Robert E. Waltermire, Senior VP, Chief Pharma Development at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 2,454 shares at $340.99 ($837K) on 2025-02-28, disclosed to the SEC on 2025-03-04.
Open-market sale of $837k MDGL by Senior VP, Chief Pharma Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $340.99 | 1,052 | $359K | 42.9% |
| 2 | $340.99 | 1,052 | $359K | 42.9% |
| 3 | $341.55 | 175 | $60K | 7.1% |
| 4 | $341.55 | 175 | $60K | 7.1% |
| Total | $341.07 avg | 2,454 | $837K | 100% |
| Filing → |
| MDGL | SELL | 2025-01-17 | $242K | — | Filing → |
| MDGL | SELL | 2024-06-18 | $532K | — | Filing → |
| MDGL | SELL | 2024-06-14 | $570K | — | Filing → |